Multicenter SPAN Trial of Fasudil in Ischemic Stroke

Overview of attention for article published in Stroke, May 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

news: 1 news outlet
twitter: 5 X users

facebook: 1 Facebook page

Readers on

mendeley: 2 Mendeley

So far, Altmetric has seen 8 X posts from 5 X users, with an upper bound of 851 followers.

2020〜2025年の米国でのポスドクLifeでは、SPAN1と2の実働部隊として非常に良い経験ができました。 Rhoキナーゼ阻害剤のファスジルの効果検証で筆頭論文をStrokeに出せたことも幸いです。脳卒中への脳保護薬開発は非常に大変ですが、諦めずにトライしたいですね https://…

RT @lydenlab: Another paper from our SPAN 1.0 studies is out in @StrokeAHA_ASA. Fasudil, a Rho-kinase (ROCK) inhibitor, improved the primar…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 4 additional X posts.